ClinicalTrials.gg
RecruitingNCT07230288Updated Sep 3, 2026

Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis

A Phase 2 interventional study of ABBV-142 and Placebo for ABBV-142 in Idiopathic Pulmonary Fibrosis, sponsored by AbbVie. Recruiting at 57 sites in 17 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
165
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States — 37 open to participants now, 51 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · United States.

Planned enrollment
51st of 188
165 · median 61
Started
2026
with 15 others
Phase 2
82 of 236
13 open now
Primary completion
2029-09
later than 40 of 50 live
Registered
223rd of 236
by date

Among the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, this one is the 51st largest by planned enrollment of the 188 interventional ones that give a count, is one of 16 that started in 2026, is one of 82 in phase 2, reaches primary completion later than 40 of the 50 other live ones, and was the 223rd registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 122 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

37 of the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 84 Idiopathic Pulmonary Fibrosis studies recruiting now, 55 (65%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, or all of them as a file.
02

Study summary

Idiopathic Pulmonary Fibrosis (IPF) is a rare, long-lasting lung disease that causes scarring of lung tissue, shortness of breath, and loss of lung function. IPF leads to significant loss of quality of life and shortened lifespan. This study is a platform study evaluating different types of treatments in patients with IPF. A platform study is a type of study that uses a single master protocol to evaluate different study treatments allowing for new study treatments or substudies to be added or closed over time. The main goals of the study are to evaluate the safety, tolerability (the degree to which the adverse symptoms can be handled by the patients during the study) and efficacy (how well study treatment works) of the study treatments, including ABBV-142 in Substudy 1 (SS1).

ABBV-142 is an investigational drug being developed for the treatment of IPF. In SS1, participants will be randomly assigned to one of the 2 groups to receive either ABBV-142 or a matching placebo. This study is "double-blind", meaning that neither the participants nor the study doctors know who is given which study treatment. Approximately 165 adult participants with IPF will be enrolled in approximately 125 sites across the world.

Participants will receive ABBV-142 or matching placebo for 52 weeks during the double-blind treatment period. Eligible participants may receive ABBV-142 for 52 weeks in open-label treatment period. All participants will be followed for 120 days.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis

Keywords

  • Idiopathic Pulmonary Fibrosis
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Diagnosis of Idiopathic Pulmonary Fibrosis (IPF) within 7 years prior to screening, confirmed by the investigator at screening that is supported by centrally read chest high-resolution computed tomography (HRCT) obtained within 12 months of the screening visit and verification of usual interstitial pneumonia(UIP) or probable UIP.

Exclusion criteria

Exclusion Criteria:

  • History of stroke within 6 months prior to screening
  • In the opinion of the investigator, other pulmonary abnormalities
  • History of any up to 5 years prior screening visit, except for successfully treated nonmelanoma skin cancer or localized carcinoma in situ of the cervix.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
165 participants (estimated)

Study arms

  • Experimental
    Substudy 1: ABBV-142

    Participants will receive ABBV-142 for 52 week during double-blind treatment period. Eligible participants may receive ABBV-142 for 52 weeks during open-label treatment period.

    Drug: ABBV-142

  • Placebo comparator
    Substudy 1: Placebo for ABBV-142

    Participants will receive placebo for ABBV-142 for 52 week during double-blind treatment period. Eligible participants may receive ABBV-142 for 52 weeks during open-label treatment period.

    Drug: ABBV-142 · Drug: Placebo for ABBV-142

Interventions

  • DrugABBV-142

    ABBV-142

  • DrugPlacebo for ABBV-142

    Placebo for ABBV-142

06

What researchers measure

Primary outcomes

  1. Absolute Change From Baseline in Forced Vital Capacity (FVC) (mL)

    FVC is a test that measures the total amount of air a person can fully exhale from their lungs after a deep inhalation. A low FVC can demonstrate reduced lung capacity.

    Time frame: Week 24

  2. Percentage of Participants with Adverse Events (AE)

    An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. The investigator assesses the relationship of each event to the use of study drug.

    Time frame: Up to approximately 52 weeks

Secondary outcomes

  1. Absolute Change From Baseline in Forced Vital Capacity (FVC) (mL)

    FVC is a test that measures the total amount of air a person can fully exhale from their lungs after a deep inhalation. A low FVC can demonstrate reduced lung capacity.

    Time frame: Week 52

  2. Relative Change From Baseline in FVC (mL)

    FVC is a test that measures the total amount of air a person can fully exhale from their lungs after a deep inhalation. A low FVC can demonstrate reduced lung capacity.

    Time frame: Week 24

  3. Relative Change From Baseline in FVC (ml)

    FVC is a test that measures the total amount of air a person can fully exhale from their lungs after a deep inhalation. A low FVC can demonstrate reduced lung capacity.

    Time frame: Week 52

  4. Absolute Change from Baseline in FVC% predicted

    FVC is a test that measures the total amount of air a person can fully exhale from their lungs after a deep inhalation. A low FVC can demonstrate reduced lung capacity.

    Time frame: Up to approximately 52 weeks

  5. Relative Change From Baseline in FVC% predicted

    FVC is a test that measures the total amount of air a person can fully exhale from their lungs after a deep inhalation. A low FVC can demonstrate reduced lung capacity.

    Time frame: Up to approximately 52 weeks

  6. Change From Baseline in Living with Pulmonary Fibrosis (L-PF) Overall Score

    L-PF questionnaire is a 49-item disease specific PRO that assesses symptoms and impacts of living with pulmonary fibrosis among participants with fibrosing interstitial lung disease (ILD). Summary scores range from 0-100, the higher the score the greater the impairment.

    Time frame: Up to approximately 52 weeks

  7. Time to First Absolute Decline From Baseline in FVC% Predicted of >= 10%

    FVC is a test that measures the total amount of air a person can fully exhale from their lungs after a deep inhalation. A low FVC can demonstrate reduced lung capacity.

    Time frame: Up to approximately 52 weeks

  8. Time to First Relative Decline From Baseline in FVC% Predicted of >= 10%

    FVC is a test that measures the total amount of air a person can fully exhale from their lungs after a deep inhalation. A low FVC can demonstrate reduced lung capacity.

    Time frame: Up to approximately 52 weeks

  9. Time to First Absolute Decline From Baseline in FVC% Predicted >= 5%

    FVC is a test that measures the total amount of air a person can fully exhale from their lungs after a deep inhalation. A low FVC can demonstrate reduced lung capacity.

    Time frame: Up to approximately 52 weeks

  10. Time to First Relative Decline From Baseline in FVC% Predicted >= 5%

    FVC is a test that measures the total amount of air a person can fully exhale from their lungs after a deep inhalation. A low FVC can demonstrate reduced lung capacity.

    Time frame: Up to approximately 52 weeks

07

Study locations

57 of 57 sites recruiting
  • The University of Alabama at Birmingham /ID# 277613
    Birmingham, Alabama 35233, United States
    Recruiting
  • Sec Clinical Research - East - Dothan - Graceland /ID# 278328
    Dothan, Alabama 36305, United States
    Recruiting
  • Clinical Research Specialists - Kissimmee /ID# 279184
    Kissimmee, Florida 34746, United States
    Recruiting
  • Christie Clinic on University /ID# 277871
    Champaign, Illinois 61820, United States
    Recruiting
  • University of Michigan Health System - Ann Arbor /ID# 279994
    Ann Arbor, Michigan 48109, United States
    Recruiting
  • Henry Ford Hospital /ID# 277843
    Detroit, Michigan 48202, United States
    Recruiting
  • Hannibal Regional Hospital /ID# 277984
    Hannibal, Missouri 63401, United States
    Recruiting
  • Jefferson Health Honickman Center /ID# 279127
    Philadelphia, Pennsylvania 19107, United States
    Recruiting
  • Inova Fairfax Hospital /ID# 278469
    Falls Church, Virginia 22042, United States
    Recruiting
  • Virginia Commonwealth University Medical Center /ID# 277992
    Richmond, Virginia 23219, United States
    Recruiting
  • Lung Research Queensland /ID# 278838
    Nundah, Queensland 4012, Australia
    Recruiting
  • Eastern Health /ID# 278245
    Box Hill, Victoria 3128, Australia
    Recruiting
  • University Multiprofile Hospital for Active Treatment Dr. Georgi Stranski /ID# 277845
    Pleven, 5800, Bulgaria
    Recruiting
  • University Multiprofile Hospital For Active Treatment Sveti Georgi - Plovdiv /ID# 279367
    Plovdiv, 4002, Bulgaria
    Recruiting
  • Acibadem City Clinic Tokuda University Hospital EAD /ID# 277846
    Sofia, 1407, Bulgaria
    Recruiting
  • Diagnostic Consultative Center Convex /ID# 277848
    Sofia, 1680, Bulgaria
    Recruiting
  • Diagnostic Consultative Center Convex /ID# 277849
    Sofia, 1680, Bulgaria
    Recruiting
  • Centre d'Investigation Clinique Mauricie /ID# 277949
    Trois-Rivières, Quebec G8T 7A1, Canada
    Recruiting
  • Hopital Arnaud de Villeneuve /ID# 278322
    Montpellier, Herault 34090, France
    Recruiting
  • Centre Hospitalier Universitaire de Rennes - Hopital Pontchaillou /ID# 278333
    Rennes, Ille-et-Vilaine 35033, France
    Recruiting
  • Hopital Avicenne /ID# 279212
    Bobigny, Île-de-France Region 93000, France
    Recruiting
  • Klinikum Konstanz /ID# 278139
    Konstanz, Baden-Wurttemberg 78464, Germany
    Recruiting
  • Caritas-Krankenhaus St. Maria gGmbH /ID# 278138
    Donaustauf, Bavaria 93093, Germany
    Recruiting
  • University General Hospital of Patras /ID# 277726
    Pátrai, Achaia 26504, Greece
    Recruiting
  • General Hospital of Chest Diseases of Athens SOTIRIA /ID# 277724
    Athens, Attica 11527, Greece
    Recruiting
  • University General Hospital of Heraklion /ID# 277717
    Heraklion, Crete 71500, Greece
    Recruiting
  • University Hospital of Ioannina /ID# 277719
    Ioannina, 45500, Greece
    Recruiting
  • General Hospital of Thessaloniki George Papanikolaou /ID# 277819
    Thessaloniki, 57010, Greece
    Recruiting
  • NHO Kinki Chuo Chest Medical Center /ID# 280225
    Sakai-shi, Osaka 591-8555, Japan
    Recruiting
  • Vitamed Galaj i Cichomski Sp.j. /ID# 278145
    Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-079, Poland
    Recruiting
  • Unidade Local de Saude de Loures-Odivelas-Hospital Beatriz Angelo /ID# 278357
    Loures, Lisbon District 2674-514, Portugal
    Recruiting
  • Unidade Local de Saude de Matosinhos EPE /ID# 277980
    Senhora da Hora, Porto District 4464-513, Portugal
    Recruiting
  • Unidade Local de Saude do Algarve, EPE /ID# 278388
    Faro, 8000-386, Portugal
    Recruiting
  • University Clinical Center Serbia /ID# 278496
    Belgrade, Beograd 11000, Serbia
    Recruiting
  • Institute For Pulmonary Diseases Of Vojvodina /ID# 278499
    Kamenitz, Sremski Okrug 21208, Serbia
    Recruiting
  • Dr Hannes J van Rensburg inc /ID# 278278
    Cape Town, Western Cape 7130, South Africa
    Recruiting
  • Dr JM Engelbrecht Trial Site /ID# 278287
    Somerset West, Western Cape 7130, South Africa
    Recruiting
  • Inje University Haeundae Paik Hospital /ID# 278000
    Busan, Busan Gwang Yeogsi 48108, South Korea
    Recruiting
  • The Catholic University Of Korea, Bucheon St. Mary'S Hospital /ID# 278068
    Bucheon-si, Gyeonggido 14647, South Korea
    Recruiting
  • Seoul National University Bundang Hospital /ID# 278059
    Seongnam-si, Gyeonggido 13620, South Korea
    Recruiting
  • Yonsei University Health System Severance Hospital /ID# 278166
    Seoul, Seoul Teugbyeolsi 03722, South Korea
    Recruiting
  • Hospital Clinico Universitario de Valencia /ID# 277921
    Valencia, 46010, Spain
    Recruiting
  • Hospital Universitari i Politecnic La Fe /ID# 278478
    Valencia, 46026, Spain
    Recruiting
  • Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 278029
    Kaohsiung City, 807, Taiwan
    Recruiting
  • Kaohsiung Chang Gung Memorial Hospital /ID# 278043
    Kaohsiung City, 833, Taiwan
    Recruiting
  • China Medical University Hospital /ID# 278039
    Taichung, 40447, Taiwan
    Recruiting
  • National Taiwan University Hospital /ID# 278041
    Taipei, 100, Taiwan
    Recruiting
  • Taipei Veterans General Hospital /ID# 278038
    Taipei, 112, Taiwan
    Recruiting
  • Linkou Chang Gung Memorial Hospital /ID# 278042
    Taoyuan City, 333, Taiwan
    Recruiting
  • Gulhane Egitim ve Arastirma Hastanesi /ID# 278944
    Ankara, Antalya 06010, Turkey (Türkiye)
    Recruiting
  • Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi /ID# 278943
    Istanbul, 34899, Turkey (Türkiye)
    Recruiting
  • Royal Papworth Hospital NHS Foundation Trust /ID# 278055
    Cambridge, Cambridgeshire CB2 0AY, United Kingdom
    Recruiting
  • Edinburgh Royal Infirmary - NHS Lothian /ID# 278631
    Edinburgh, Edinburgh, City of EH16 4SA, United Kingdom
    Recruiting
  • UCLH NHS FT - University College Hospital /ID# 279198
    London, Greater London NW1 2BU, United Kingdom
    Recruiting
  • Royal Brompton Hospital /ID# 278007
    London, Greater London SW3 6NP, United Kingdom
    Recruiting
  • University Hospital Southampton /ID# 278223
    Southampton, Hampshire SO16 6YD, United Kingdom
    Recruiting
  • Norfolk and Norwich University Hospital /ID# 278224
    Norwich, Norfolk NR4 7UY, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Sep 2029, 44 months after the start.

Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 45. This study's planned 44 months is above that.

Counting every sponsor, half of 76 studies reached it within 29 months; a quarter within 21 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Nov 17, 2025
StartActual
Jan 23, 2026
Primary completionEst.
Sep 2029
CompletionEst.
Sep 2029
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07230288
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Nov 17, 2025
Start date
Jan 23, 2026
Primary completion
Sep 2029 (estimated)
Completion
Sep 2029 (estimated)
Last update
Sep 3, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion